Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating DNA: a new diagnostic gold mine?

Annemarie Ziegler1, Uwe Zangemeister-Wittke, Rolf A Stahel

  • 1Departement für Innere Medizin, Onkologie Abteilung, Universitätsspital Zürich, Haeldeliweg 4, Switzerland. annemarie.ziegler@dim.usz.ch

Cancer Treatment Reviews
|November 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Correction: Targeting the Phosphoinositide 3-Kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.

JCO precision oncology·2025
Same author

ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.

Lung cancer (Amsterdam, Netherlands)·2024

Tumor-derived cell-free DNA (cfDNA) in blood shows promise as a non-invasive biomarker for cancer diagnosis and monitoring. Detecting specific DNA alterations in cfDNA aids in understanding disease progression and prognosis.

Area of Science:

  • Molecular Oncology
  • Biomarker Discovery
  • Liquid Biopsy

Background:

  • Cell-free DNA (cfDNA) released from dying tumor cells circulates in the bloodstream.
  • Tumor-specific DNA alterations in cfDNA are detectable in patients with various cancers.
  • cfDNA analysis offers a minimally invasive approach for cancer detection.

Purpose of the Study:

  • To review current research on circulating tumor DNA (ctDNA) as a biomarker.
  • To emphasize technical challenges and clinical data relevant to ctDNA analysis.
  • To explore the potential of ctDNA in molecular diagnostics and prognosis.

Main Methods:

  • Review of existing scientific literature on cfDNA and ctDNA.
  • Analysis of studies demonstrating tumor-specific DNA alterations in patient plasma/serum.

Related Experiment Videos

  • Focus on technical aspects of cfDNA recovery and analysis.

    • Main Results:

    • Demonstration of tumor-specific DNA alterations in cfDNA from blood samples.
    • Evidence supporting the use of cfDNA as a surrogate tumor marker.
    • Identification of potential applications in early diagnosis and disease monitoring.

    Conclusions:

    • Circulating tumor DNA is a valuable tool for minimally invasive cancer detection and monitoring.
    • Further research into technical issues is crucial for clinical implementation.
    • cfDNA analysis holds significant potential for improving cancer diagnostics and patient prognosis.